Bielefeld, Germany
Semalytix, a pioneering startup founded in 2015 and headquartered in Germany, focuses on revolutionizing pharmaceutical drug development through AI-driven solutions. Their flagship product, the Pharos platform, leverages cutting-edge AI and LLM technology to analyze vast amounts of real-world data from social media, forums, and CRM systems. This allows Semalytix to provide pharmaceutical companies with deep insights into patient and healthcare practitioner perceptions and experiences.
With a team of 75 employees, Semalytix has successfully executed over 40 projects, generating a total revenue of EUR 3.8M between 2015 and 2019. Their innovative approach offers pharmaceutical giants critical understanding of patient needs, ultimately aiming to enhance well-being and transform lives.
The company secured a €2.00M Series A Extension investment in February 2021, with backing from NRW BANK, positioning itself as a significant player in AI-powered patient-focused solutions for the pharmaceutical industry.
Pharos Marine Automatic Power